EligibleTrials

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Recruiting · NCT07101094 · Observational (researchers observe without assigning treatment) · Lead sponsor: Bristol-Myers Squibb

View the official record on ClinicalTrials.gov →
Schizophrenia

Interventions studied

xanomeline and trospium chloride (X/T) therapy

What this trial is about

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

20 locations listed across 12 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.